# Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

> **NCT05218603** · — · UNKNOWN · sponsor: **PETHEMA Foundation** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Myeloma
- Non-eligible for Autologous Stem Cell Transplantation (ASCT)

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT05218603
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-30
- **Primary completion:** 2025-11-06
- **Final completion:** 2025-11-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218603, "Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05218603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*